Pancreatic cancer is among the leading causes of cancer death in the USA, with limited effective treatment options. A major contributor toward the formation and persistence of pancreatic cancer is the dysregulation of the hepatocyte growth factor (HGF)/Met (HGF receptor) and the macrophage-stimulating protein (MSP)/Ron (MSP receptor) systems. These systems normally mediate a variety of cellular behaviors including proliferation, survival, and migration, but are often overactivated in pancreatic cancer and contribute toward cancer progression. Previous studies have shown that HGF must dimerize to activate Met. Small-molecule antagonists with homology to a 'hinge' region within the putative dimerization domain of HGF have been developed that bind to HGF and block dimerization, therefore inhibiting Met signaling. Because of the structural and sequence homology between MSP and HGF, we hypothesized that the inhibition of HGF by the hinge analogs may extend to MSP. The primary aim of this 'proofof-concept' study was to determine whether hinge analogs could inhibit cellular responses to both HGF and MSP in pancreatic cancer cells. Our results showed that these compounds inhibited HGF and MSP activity. Hinge analog treatment resulted in decreased Met and Ron activation, and suppressed malignant cell behaviors including proliferation, migration, and invasion in pancreatic cancer cells in vitro. These results suggest that the hinge analogs represent a novel group of molecules that may offer a therapeutic approach for the treatment of pancreatic cancer and warrant further development and optimization.
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Introduction
Pancreatic cancer is among the deadliest malignancies in the USA, with nearly 40 000 deaths occurring in 2015 [1] . The long-term prognosis of pancreatic cancer patients is exceptionally poor, with a 5-year survival rate of ∼ 7% [1, 2] . Pancreatic cancer is frequently associated with aggressive local invasion and formation of distant metastases even at early stages, which contributes toward the poor median survival time after diagnosis of only 4-6 months [2, 3] . Surgical resection is often not possible, with ∼ 85% of patients excluded as candidates for surgery [3] . Pancreatic cancer also shows marked resistance to currently available chemotherapeutic agents [4] . This leaves patients with few treatment options and highlights the urgent need for the development of novel therapeutic strategies for the treatment of pancreatic cancer.
Growth factors have long been known to play important roles in tumor formation and progression [5] . Of particular importance to cancers of epithelial origins are the hepatocyte growth factor (HGF) and macrophage-stimulating protein (MSP), which share 45% sequence homology and belong to the plasminogen-related growth factor family [6] . These growth factors mediate a variety of cellular effects in normal tissues including proliferation, migration, and differentiation [7, 8] . Mesenchymal cells are the primary source of HGF and it is secreted as an inactive pro-HGF before being cleaved by serine proteases into the mature heterodimer consisting of disulfide-linked α-chain and β-chain [9] . MSP is secreted into circulation predominantly by hepatocytes as pro-MSP and similarly undergoes proteolytic cleavage into the active αβ heterodimer [10] . The receptor tyrosine kinase, Met, is the only known receptor for HGF and is expressed widely in many cell types. Ron, the receptor tyrosine kinase for MSP, is primarily expressed in epithelial cells and dysregulation of the MSP/Ron or HGF/Met systems is Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website (www.anti-cancerdrugs.com).
associated with increased malignant cell behaviors and a poor prognosis [11, 12] . Overexpression of these systems has been observed in various cancers, including pancreatic cancer [13, 14] . Previous studies have reported that HGF and MSP can induce pancreatic cancer cell proliferation, promote invasive phenotypes, and contribute toward the progression of the disease [15, 16] .
An essential property of HGF is that it must dimerize to activate Met as the active signaling complex of HGF : Met has been shown to exhibit a 2 : 2 stoichiometry [17, 18] . Previous work has shown that small peptides with partial or complete sequence homology to a region of HGF between the N-terminal and first Kringle domain, known as the 'linker' or the 'hinge' region, can inhibit HGF dimerization when incubated with fulllength recombinant human HGF [19] . These compounds, referred to here as hinge analogs, have been shown to bind to HGF, therefore blocking dimerization and HGF-dependent Met activation and cell behaviors [19, 20] . The primary aims of this 'proof-of-concept' study were to determine whether these compounds were capable of inhibiting both HGF-dependent and MSPdependent processes in pancreatic cancer cells and gauge the value of future development, but not the generation of an optimized drug candidate.
Given the high sequence homology between HGF and MSP in the 'hinge' regions between the N-terminal and the first Kringle domain, we hypothesized that the hinge analogs may also have activity toward the MSP/Ron system and could potentially act as dual HGF/MSP inhibitors. Although the mechanism by which MSP binds to and activates Ron differs from the HGF/Met system, the sequence homology between the growth factors led us to postulate that dual HGF/MSP inhibitors could be developed. The results from the present study indicate that the hinge analogs are inhibitors of the HGF/Met system in pancreatic cancer cells. Furthermore, these analogs showed activity toward MSP by inhibiting MSPdependent signaling and cell migration. Taken together, these studies indicate that hinge analogs have inhibitory activity toward both HGF and MSP, suggest that dual HGF/MSP inhibitors have therapeutic potential, and warrant future optimization as pharmaceuticals.
Materials and methods
Compounds HGF hinge (Lys-Asp-Tyr-Ile-Arg-Asn), MSP hinge (Lys-Asp-Tyr-Val-Arg-Thr), and Norleual (Nle-Tyr-Leu-ψ-(CH 2 -NH 2 ) 3-4 -His-Pro-Phe) were produced synthetically by solid-phase synthesis and obtained from RS Synthesis (Louisville, Kentucky, USA). Recombinant human HGF and MSP were acquired from R&D Systems (Minneapolis, Minnesota, USA).
Cell culture
The murine pancreatic cancer cell line LM-P was kindly provided by Dr Andrew Lowy (Department of Surgery, Division of Surgical Oncology, University of California at San Diego, Moores Cancer Center, La Jolla, California, USA) and originated from the KPC mouse model of pancreatic cancer [21] . The LM-P cells were maintained in Dulbecco's modified Eagle medium containing 10% fetal bovine serum (FBS), penicillin/streptomycin cocktail, and plasmocin. The human BxPC-3 pancreatic cancer cell line was obtained from the American Type Culture Collection (Manassas, Virginia, USA) and maintained in Roswell Park Memorial Institute media supplemented with 10% FBS, penicillin/streptomycin cocktail, and plasmocin. All cell lines were kept in a humidified 37°C incubator with 5% CO 2 .
Immunoblotting

Western blotting
To determine the effects of hinge analog treatment on HGF-dependent activation of Met, LM-P cells were grown to subconfluent levels in six-well plates, deprived of serum for 24 h, and then treated with PBS vehicle, HGF (10 ng/ml), or HGF with the indicated concentrations of either HGF hinge, MSP hinge, or Norleual for 10 min before cell harvest. Cell lysates were separated by SDS-PAGE (Bio-Rad, Hercules, California, USA), transferred to nitrocellulose membranes (Sigma-Aldrich, St Louis, Missouri, USA), and incubated with antibodies to p-Met, total Met, phosphoextracellular signal-regulated kinase (p-Erk), Erk (Erk1/2 or p44/42, referred to simply as Erk), and/or β-actin (all from Cell Signaling, Danvers, Massachusetts, USA). The effects of the hinge analogs on HGF-induced signaling were determined by treating LM-P cells with PBS, HGF (20 ng/ml), or HGF with Norleual, HGF hinge, or MSP hinge (all at 1 nmol/l) for 10 min. All treatments were prepared and incubated at 37°C for 1 h before their addition to the cells. Cell lysates were harvested using radioimmunoprecipitation assay lysis buffer (Sigma-Aldrich) containing protease and phosphatase inhibitors (Sigma-Aldrich). A 1 : 2000 primary antibody dilution was used to detect Erk bands, whereas all others were used at 1 : 1000. All blots were developed by incubation with the appropriate horseradish peroxidase conjugated secondary antibody at a concentration of 1 : 3000 (Cell Signaling). Following secondary antibody incubation, bands were detected using the enhanced chemiluminescence system (Thermo Scientific, Waltham, Massachusetts, USA) and quantified by densitometry in ImageJ (National Institutes of Health, Bethesda, Maryland, USA).
The levels of basal p-Met in LM-P samples treated with hinge analogs alone (no HGF) were determined by treating cells with PBS, HGF (20 ng/ml), or each hinge analog alone (all at 1 nmol/l). Lysates were collected and immunoblotted as described above. To characterize the response of the LM-P cells to HGF, LM-P cells were grown to near confluency, serum starved for 24 h, and then treated with various concentrations of HGF in serum-free media for 10 min. Treatment groups also included samples treated with fresh media consisting of Dulbecco's modified Eagle medium with 10% serum or conditioned media (CM). CM were collected from LM-P cultures grown for 3 days. Following treatment, the cells were harvested and cell lysates were separated by SDS-PAGE (Bio-Rad), transferred to nitrocellulose (Sigma-Aldrich), blocked in a 5% BSA solution in tris-buffered saline, and immunoblotted for p-Met, Met, and β-actin (all from Cell Signaling) at a final primary antibody concentration of 1 : 1000. Samples of CM collected over a 4-day period were separated by SDS-PAGE and immunoblotted for HGF (Santa Cruz Biotechnology Inc., Dallas, Texas, USA) at a concentration of 1 : 200.
To assess the effects of compounds on MSP-dependent signaling, BxPC-3 cells were treated for 30 min with PBS vehicle, MSP (5 nmol/l), or MSP with HGF hinge, MSP hinge, or Norleual (all at 10 nmol/l). Cell lysates were harvested and separated as described previously. Blots were probed with antibodies for phospho-Akt (Ser473) (p-Akt), Akt, and β-actin (Cell Signaling). The experiment to determine basal p-Akt levels with no addition of exogenous MSP was conducted using the same procedures and concentrations. When necessary, blots were stripped with Restore Plus stripping buffer (Thermo Scientific) and incubated with appropriate antibodies. All sample groups were performed in triplicate and each immunoblotting experiment was repeated three times.
Immunoprecipitation
The levels of phospho-Ron following treatment with MSP hinge analogs in BxPC-3 cells were assessed by immunoprecipitation using µMACS Protein A MicroBeads (Miltenyi Biotec, San Diego, California, USA). Cell lysates were incubated with 2 µg of anti-Ron antibody (Abcam, Cambridge, Massachusetts, USA) and 100 µl Protein A MicroBeads (Miltenyi Biotec) per sample for 30 min. Lysates were then passed through a magnetic separation column wherein the beads and all bound antibody : protein complexes were retained. Samples were then eluted from the column in gel loading buffer, denatured, and separated by SDS-PAGE. Gels were transferred to nitrocellulose and incubated with anti-Ron antibody (1 : 1000; Abcam) and PY20 antibodies (Abcam) at 1 : 1000 to detect phosphorylated tyrosines.
Proliferation assays LM-P cells at a density of 2.0 × 10 3 cells/well were seeded into a 96-well plate in complete media and allowed to attach overnight. Following a 24 h serum starvation, treatments including PBS vehicle, HGF (40 ng/ml) and
Norleual, MSP hinge, or HGF hinge at the indicated doses in 0.1% FBS media were added to the appropriate wells. The cells were allowed to grow for 4 days with a daily addition of Norleual, MSP hinge, HGF hinge, or vehicle. On the fourth day, WST-8 reagent [2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, monosodium salt] (Dojindo Molecular Technologies, Rockville, Maryland, USA), a tetrazolium salt that is converted into a formazan dye by viable cells, was added to the cells and the absorbance was measured at 450 nm on a BioTek Synergy 2 plate reader (BioTek Instruments Inc., Winooski, Vermont, USA).
To determine the effect of concurrent treatment of the hinge analogs with a Met kinase inhibitor, LM-P cells were prepared as described above. The Met kinase inhibitor SU11274 (Sigma-Aldrich) was prepared in dimethyl sulfoxide and added to the treatments for a final concentration of 5 µmol/l. HGF (40 ng/ml) and Norleual, MSP hinge, and HGF hinge (all at 1 nmol/l) or vehicle (dimethyl sulfoxide : PBS solution) were added to appropriate groups and cells were treated for 4 days with the daily addition of the hinge analogs or PBS. Proliferation was quantified using the WST-8 assay.
To investigate the effect of Norleual on BxPC-3 proliferation, 2.0 × 10 3 cells/well were placed in a 96-well plate and incubated overnight. The cells were deprived of serum for 24 h and then treated with PBS or Norleual at the designated concentrations for 48 h before proliferation was assessed using the WST-8 assay.
Migration assays Scratch assay
Pancreatic cancer cells were grown to near confluency in 24-well plates, serum starved overnight, and then scratched down the middle of the well with a pipette tip. Wells were then washed twice with sterile PBS to remove cell debris. Treatments containing vehicle alone (PBS), HGF (20 ng/ml), or HGF with HGF hinge, MSP hinge, or Norleual at various concentrations were added to the wells. Images were taken immediately after the addition of treatments and again at 24 h at identical stage coordinates. Images were acquired using a Nikon Eclipse Ti-E imaging system (Nikon, Melville, New York, USA) and the scratch area was analyzed and quantified using the NIS-Elements Analysis software (Nikon). The scratch borders were outlined on the time 0 images and overlaid onto the corresponding time 24 images to show the extent of migration. To test the effects of the hinge analogs on migration without the addition of exogenous HGF, identical procedures were followed, except no HGF was added to any of the treatments.
Transwell migration assay
The effect of Norleual and MSP hinge on MSP-induced migration of BxPC-3 cells was evaluated using the Transwell migration assay (Corning, Corning, New York, USA). A total of 2.0 × 10 4 BxPC-3 cells were loaded into the upper chamber of Transwell inserts (Corning) in HGF-dependent signaling is inhibited by hinge analogs in LM-P murine pancreatic cancer cells. (a-c) The hinge analog dose required for optimal p-Met inhibition was determined by immunoblotting for p-Met following treatment with HGF (10 ng/ml) and each hinge analog at several concentrations (100-1 nmol/l). β-Actin served as the loading control. reduced serum media. Media with PBS vehicle alone, MSP (5 nmol/l) alone, MSP + Norleual (10 nmol/l) or MSP hinge (10 nmol/l), or Norleual and MSP hinge alone were added to the lower chamber in 500 µl total volume and samples were incubated for 24 h. Following incubation, the cells in the upper chamber were removed with sterile swabs and migratory cells remaining on the membrane were fixed with methanol and stained with 0.5% crystal violet. Five random images were taken at × 80 magnification per insert with a digital camera attached to a Zeiss Axiovert microscope (Carl Zeiss AG, Oberkochen, Germany) and cells were counted in ImageJ image analysis software.
Invasion assay
To determine the effect of Norleual on pancreatic cancer cell invasion, 5.0 × 10 4 LM-P cells in 200 µl serum-free media were seeded into the top chamber of a Transwell (Corning) insert. The membrane of the insert was coated in Matrigel (BD Biosciences, San Jose, California, USA) to represent an extracellular matrix. 500 µl of 4% FBS media were placed in the bottom chamber and supplemented with vehicle alone (PBS), HGF (20 ng/ml) Norleual (10 nmol/l), or Norleual alone, and incubated for 72 h. Norleual was refreshed every 24 h. Following the incubation period, noninvasive cells were removed from the top of the insert with sterile cotton swabs. Invasive cells were fixed to the bottom membrane and stained with a 0.5% crystal violet solution. Images were taken at × 40 magnification to show the extent of invasion across the membrane. To quantify invasion, the dye from each insert was solubilized in a 33% acetic acid solution and placed in triplicate wells of a 96-well plate. Absorbance was measured at 600 nm. Each treatment group was performed in triplicate and the experiment was repeated three times.
Statistics
Results are expressed as mean SEM unless otherwise stated. Data were analyzed using GraphPad Prism, version 5 (GraphPad Software, La Jolla, California, USA). Differences between groups were assessed using an unpaired two-tailed Student t-test. Multiple comparisons were performed by one-way analysis of variance, followed by Tukey's post-hoc test. Differences between groups were considered statistically significant when P was less than 0.05.
Results
Hinge analogs inhibit HGF-dependent activation of Met
Pancreatic cancer cells have been shown to overexpress Met compared with normal pancreatic tissue, resulting in increased sensitivity to HGF and overactivation of the Met signaling pathway [22] [23] [24] . Previous reports from our laboratory have shown hinge analogs to inhibit Met activation by HGF in HEK293 and MDCK cells [19, 20] . LM-P cells were very responsive to HGF, showing a considerable response with respect to Met phosphorylation (activation) ( Fig. 1) . To determine the effects and optimum doses of the hinge analogs on HGF-dependent activation of Met in a pancreatic cancer cell line, LM-P cells were treated with HGF (10 ng/ml) and the hinge analogs at a dose range of 100-1 nmol/l. Immunoblotting for p-Met showed that HGF hinge, MSP hinge, and Norleual inhibited Met activation at several doses with an optimal dose of 1 nmol/l ( Fig. 1a-c) . To quantitatively assess the ability of the hinge analogs to inhibit Met activation by HGF, LM-P cells were treated with HGF in combination with the hinge analogs and levels of phospho-Met were determined by western blotting. Cells treated with HGF in combination with HGF hinge, MSP hinge, or Norleual (all at 1 nnol/l) significantly suppressed HGF-dependent activation of Met ( Fig. 1d  and e ). Phospho-Met bands were quantified by densitometry and normalized to total Met. The level of Met phosphorylation in the HGF-alone-treated samples was significantly different from that of all the other groups, indicating that all the hinge analogs could inhibit HGF activity ( Fig. 1e ). HGF has been shown to activate the Erk, pathway, which plays an integral role in cell proliferation, differentiation, and survival [25] . Treatment with HGF alone significantly increased the levels of Erk phosphorylation compared with the control. This increased Erk phosphorylation was attenuated by the addition of either MSP hinge or Norleual ( Fig. 1d and f ). Although the difference did not reach statistical significance, the addition of HGF hinge showed a similar trend with respect to HGF-dependent Erk phosphorylation. These data suggest that the hinge analogs, particularly MSP hinge and Norleual, can inhibit HGFdependent activation of Met and downstream signaling pathways.
Pancreatic cancer cell proliferation is inhibited by hinge analog treatment
Previous studies have shown that HGF can induce the proliferation of pancreatic cancer cells [13] . Thus, the effect of hinge analog treatment on exogenous HGFdependent and HGF-independent proliferation in LM-P cultures was assessed using the WST-8 proliferation assay, which measures the reductive capacity of mitochondria. First, the effect of the hinge analogs on exogenous HGF-dependent proliferation was examined. The results showed that MSP hinge and Norleual could inhibit almost all of the proproliferative effects of HGF, bringing the proliferation levels to near or below control values, whereas HGF hinge exerted no significant effect ( Fig. 2a-c) . Interestingly, in the absence of exogenous HGF, all hinge compounds could significantly suppress the proliferation of the LM-P cells at several doses ( Fig. 2d-f ), suggesting that the LM-P cells have an HGF/ Met autocrine loop and that its interruption inhibits proliferation.
To verify that the mechanism underlying the inhibition of LM-P proliferation by the hinge analogs was mediated by the blockade of the HGF/Met system, the Met kinase inhibitor SU11274 was added to the LM-Ps in combination with each hinge analog (Fig. 2g ). SU11274 could completely abolish the proproliferative effect of exogenous HGF and, as expected, if an autocrine loop was operative, suppress proliferation in the vehicle group. This again posits that some basal Met activity contributes toward proliferation, possibly as a result of HGF autocrine activation. In the presence of the Met kinase inhibitor, the impact of the hinge analogs on proliferation was completely occluded, indicating that the hingedependent inhibition shown in Fig. 2d-f was likely reliant on HGF/Met system blockade.
LM-P cells secrete HGF in culture and maintain an HGF/Met autocrine loop
As indicated above, the ability of the hinge analogs and the Met inhibitor, SU11274, to suppress basal proliferation in the LM-P cells suggests that an HGF/Met autocrine loop is operative in these cells. If true, this could provide a partial explanation for the aggressive nature of LM-Ps, which were originally derived from liver metastases in Kras G12D/ + , LSL-Trp53 R172H/ + , and Pdx-1-Cre mice [21] . To begin to provide a framework to assess the responsiveness of LM-P cells to endogenous HGF produced in an autocrine manner, a dose-response curve of phospho-Met levels was developed over a range of exogenously applied HGF. As indicated earlier, the addition of exogenous HGF to LM-P cells increased levels of Met phosphorylation in a dose-dependent manner (Fig. 3a) . Blots were quantified by densitometry after normalizing p-Met bands to β-actin (Fig. 3b ). Previous studies have shown HGF expression in pancreatic cancer cells [23] , and given the results of the proliferation assays ( Fig. 2) , it seemed probable that the LM-P cells express HGF. To determine whether HGF is produced by LM-P cells, CM were collected from LM-P cultures after 72 h and applied to separate populations of serum-starved LM-P cells. Met activation was significantly increased in the CM-treated samples compared with the cells treated with FM ( Fig. 3a  and b) . The presence of HGF in the CM was confirmed by immunoblotting ( Fig. 3c) , showing an accumulation of HGF in the media that increased over time. These results indicate that the phosphorylation of Met observed following CM treatment is from HGF secreted by the LM-P cells and indicates the presence of an HGF autocrine loop.
HGF-dependent migration is suppressed by MSP hinge and Norleual
HGF plays a critical role in the induction of metastatic behavior and acts as a potent activator of motility in various carcinomas, including pancreatic cancer [26, 27] .
To determine the effect of hinge analog treatment on pancreatic cancer cell migration, the scratch (wound healing) assay was used. HGF significantly increased migration of the LM-P cells compared with the untreated control as shown by the higher number of cells within the scratch area following incubation ( Fig. 4a-d ). Similar to the results of the proliferation assay ( Fig. 2a ), HGF hinge exerted no discernible effect on the activity of exogenous HGF as the level of migration in the groups treated with HGF hinge was similar to that of the HGF-alone group (Fig. 4b) . However, the addition of MSP hinge and Norleual at several concentrations abolished the promigratory effect of HGF and brought migration levels to at or near control levels ( Fig. 4c and d) . Scratch assays in the absence of exogenous HGF showed significant inhibition of migration in the presence of MSP hinge and less minor inhibition of migration by HGF hinge and Norleual ( Supplementary Fig. 1 , Supplemental digital content 1, http://links.lww.com/ACD/A164). These data suggest that MSP hinge and Norleual are effective inhibitors of HGFdependent migration.
Norleual inhibits HGF-induced invasion in pancreatic cancer cells
HGF has been shown to promote invasive phenotypes of several types of human carcinomas, including lung, bladder, and pancreatic cancer [16, 28] . The establishment of distant metastases and the aggressive invasion of local tissues contributes toward the poor clinical outcome of pancreatic cancer [29] . To evaluate the effect of Norleual on HGF-dependent invasion in LM-P cells, the Transwell invasion assay was used. Application of HGF significantly increased invasion over control and treatment with Norleual suppressed the proinvasive effect ( Fig. 5 ). When HGF was in the presence of Norleual, the levels of invasion were slightly below control levels. Taken together, these results indicate that Norleual can sufficiently inhibit HGF-induced invasion.
Hinge analogs inhibit MSP-dependent cell signaling in BxPC-3 cells
Having shown that the hinge analogs could inhibit HGF activity, and given the similarities between HGF and MSP, we next sought to determine whether these compounds had activity toward MSP. Like HGF, MSP plays important roles in the progression of pancreatic cancer, including stimulating cell migration and invasion [30] . Activation of Ron by MSP induces a wide array of biological effects through various signaling cascades including the JNK, MAPK, β-catenin, and PI3K-Akt pathways, which have been shown to mediate a variety of cell behaviors including motility and cell survival [31] . To determine the effect of hinge analog treatment on MSPinduced Akt activation, BxPC-3 cells were treated with MSP alone or in combination with HGF hinge, MSP hinge, or Norleual, and levels of p-Akt were measured. MSP stimulated the phosphorylation of Akt over control levels, but the MSP-dependent activation of Akt was significantly suppressed by cotreatment with all of the hinge compounds tested ( Fig. 6a and b) . Treatment of the BxPC-3 cells with the hinge analogs alone (no MSP) did not inhibit basal levels of p-Akt compared with the control (Fig. 6c ), suggesting that the inhibition of p-Akt shown in Fig. 6a and b occurred through inhibition of the exogenous MSP activity. To further investigate whether the inhibition of p-Akt occurred through the MSP/Ron system, samples treated with MSP the indicated hinge compound were harvested, immunoprecipitated with a Ron antibody, and immunoblotted with PY20, a phosphotyrosine-specific antibody, to determine levels of MSP-induced Ron phosphorylation. An observable increase in Ron phosphorylation over control was observed when cells were incubated with MSP; however, in the presence of the hinge analogs, this MSPdependent effect was suppressed (Fig. 6d ). This result indicates that the inhibition of p-Akt was most likely through suppression of MSP activity and Ron activation upstream of the PI3K-Akt pathway.
MSP-induced migration is suppressed by Norleual and MSP hinge
Given that the hinge analogs inhibited MSP-induced signaling, we next investigated the effects of hinge analogs on MSP-dependent cell migration. MSP treatment stimulated the migration of the BxPC-3 cells over the untreated control groups, whereas cotreatment of MSP and MSP hinge inhibited the increase in migration (Fig. 7a and c) . Similar results were found when cells were treated with Norleual and MSP (Fig. 7b and c) . In both sets of experiments, MSP hinge and Norleual significantly inhibited the promigratory effects of MSP and repressed the migratory behavior to near-control levels.
These results indicate that the hinge compounds are capable of inhibiting MSP-dependent pancreatic cancer cell behaviors, and suggests that the hinge analogs are disrupting the formation or the stability of the MSP/Ron signaling complex.
Discussion
Every hinge analog inhibited HGF-dependent and MSPdependent signaling and cellular activity, albeit to varying degrees. The hinge analogs showed a broad effective dose range with inhibition of signaling or behaviors observed at doses between 10 and 0.01 nmol/l, with consistent activity for most assays at 10 and 1 nmol/l. HGF hinge and MSP hinge seemed to have a smaller effective dose range, whereas Norleual activity was observed in some cases as low as 0.01 nmol/l (Figs 1, 2  and 4 ). This variability is likely the result of variable exposure time to biological samples in different assays and the metabolic stability of the individual analogs. Although extensive dose responses were not developed for each assay, several experiments showed U-shaped dose-response curves in which higher concentrations showed diminished inhibitory activity (Figs 2 and 4) . This dose-response pattern is not uncommon and has been reported previously with other antitumor proteins [32] and may be the result of a number of mechanisms including the oligomerization of compounds at high concentrations, differential interaction with opposing allosteric sites with different binding affinities, and offtarget effects. HGF hinge could inhibit HGF-induced Met phosphorylation when HGF was at a concentration of 20 ng/ml ( Fig. 1d and e ), but did not inhibit HGF-dependent proliferation at the same HGF concentration ( Fig. 2a ). As mentioned above, this difference is likely a reflection of the compound's metabolic stability and exposure to degradative enzymes as the exposure time of drug for tissue was only 10 min in p-Met immunoblots, but 96 h in the proliferation assay. In addition, differences in target affinity among the analogs could be contributors to response variability. Higher affinity interactions would result in slower off-rates after target binding, thus limiting exposure of drugs to the activity of degradative enzymes. For example, interaction of HGF hinge and HGF may be more transient than the association of MSP hinge or Norleual with HGF, if the former has a lower binding affinity, increasing the exposure of unbound drug to the degradative environment. Also, HGF hinge could inhibit proliferation when no exogenous HGF was added, but not when HGF at 20 ng/ml was present ( Fig. 2a and d) . Although it will need to be verified experimentally, considerations of higher target affinity and metabolic stability may underlie the superior inhibitory capabilities of MSP hinge and Norleual compared with HGF hinge.
The LM-P cell line is derived from liver metastases of a model of pancreatic cancer using KPC (Kras G12D/ + , LSL-Trp53 R172H/ + , and Pdx-1-Cre mice) mice [21] . Similar to over 90% of pancreatic cancers, the LM-Ps express constitutively active Kras, which plays a significant role in pancreatic cancer carcinogenesis [33] . Recent studies have shown that Met and Ron signaling mediates Kras oncogene addiction in pancreatic cancer by enhancing Kras activation [15, 34] . Given the importance of HGF/ Met and MSP/Ron in pancreatic cancer and the effects of the hinge analogs in both the Kras mutant (LM-P) and the Kras wild-type (BxPC-3) cell lines, these results suggest that inhibition of Met and Ron would likely have considerable anticancer activity irrespective of Kras expression. However, this supposition will be tested in future studies utilizing human cell lines expressing oncogenic Kras including MIA PaCa-2 or PANC-1.
One finding of these studies was the presence of an autocrine loop in the LM-P cell line (Fig. 3) . Inhibition of this autocrine activity explains the ability of several hinge analogs to suppress proliferation ( Fig. 2) and migration ( Supplementary Fig. 1 , Supplemental digital content 1, http://links.lww.com/ACD/A164, which shows the results of hinge analogs alone on LM-P migration) in the absence of exogenously applied HGF. The nearly nondetectable basal p-Met levels (Fig. 1g ) are in concert with the expected low levels of HGF present in an immunoassay system because of the use of washed cells and short treatment duration (10 min).
The superior inhibitory effects of MSP hinge and Norleual led us to exclude HGF hinge from several assays including the Transwell migration and invasion studies, and focus on MSP hinge and particularly Norleual. We chose Norleual to test for inhibition of HGF-dependent invasive behavior (Fig. 5 ), and Norleual could significantly block the proinvasive effects of exogenously applied HGF. Although not quite statistically significant, there was a clear trend of inhibition on comparing the Norleual and control groups, again supporting the presence of a critical autocrine loop that contributes toward the invasive activity of the cancer cells. The importance of this autocrine activity to the phenotype of these cells is further shown in the proliferation experiments, where Norleual addition could decrease proliferation in the absence of exogenously applied HGF (Fig. 2f ).
In agreement with previous reports from our laboratory [19, 20] , these results further indicate that the mechanism of action of the hinge analogs in the LM-P studies is through inhibition of the HGF/Met system. Kawas and colleagues showed that Norleual and HGF hinge competitively bind to HGF and prevent Met activation. Studies with a control peptide of identical size did not have inhibitory activity, indicating that the sequence and/ or structure of the hinge analogs are critical for HGF antagonism [19] . The capacity of a Met kinase inhibitor to occlude inhibition of proliferation observed with hinge analogs further confirms the specificity of their interaction to the HGF/Met system (Fig. 2g ). In addition, and as expected, Norleual exerted no effect on BxPC-3 proliferation (Fig. 2h) , a cell line that does not produce HGF and thus has no functional autocrine loop [29, 35] . Together, these data support a mechanism of action dependent on the blockade of the HGF/Met system. An investigation of the effects of hinge analogs on MSPdependent activity in cancer cells had not been reported previously before this study. BxPC-3 cells were used for the MSP experiments as recombinant human MSP had no effect on the migration of the murine LM-P cell line (data not shown). The hinge analogs inhibited both MSP-dependent Ron and Akt activation, but had no effect on basal p-Akt levels, consistent with the absence of an MSP/Ron autocrine loop in these cells (Fig. 6 ). Immunoblots of CM from these cells did not detect MSP (data not shown). In agreement with these observations, MSP hinge and Norleual inhibited MSP-induced BxPC-3 migration, but did not significantly alter basal migration (Fig. 7) . Our results indicate that the hinge analogs are not only capable of inhibiting the HGF/Met system but may also inhibit MSP/Ron.
Although HGF and MSP share considerable sequence homology, the mechanism of binding and interaction of the ligand with the receptor differ significantly. The formation and biological relevance of HGF dimers has been well established [17, 18] and previous results from our laboratory with compounds that block HGF dimerization, including HGF hinge and Norleual, support this model [19, 20] . Kawas et al. [19] have previously shown that Norleual and HGF hinge bind directly to HGF, thereby preventing HGF dimer formation and Met activation. Studies involving the NK1 fragment, a naturally occurring HGF splice variant, have shown that the dimer interface consists of the residues within the hinge region including those that comprise HGF hinge (K122-N127) [36, 37] . Mutagenesis studies carried out by Youles and colleagues showed that Y124A mutants could not form dimers, whereas crystal structures of the dimer interface showed extensive hydrogen bonding involving N127, and hydrophobic interactions through Y124, between the adjacent hinge regions [17, 36, 37] . These studies indicate the importance of the hinge region in the formation of HGF dimers and show that dimerization occurs in part by the association between the hinge regions of adjoining HGF monomers. Therefore, we have proposed that hinge analogs block HGF dimerization by binding to HGF and allosterically inhibiting association with a second HGF monomer, therefore blocking HGF activation. Although this model is best suited for HGF hinge in terms of the mechanism for HGF inhibition, given the sequence homology and inclusion of the tyrosine, which is important for hydrophobic interactions, we believe that it extends to Norleual and MSP hinge as well.
Determining whether MSP hinge binds to HGF directly, as we have observed with HGF hinge and Norleual, as well as investigating the location of hinge analog binding to HGF will be the focus of future studies.
Unlike the association of HGF/Met, the currently accepted model of Ron activation by MSP does not include MSP dimerization [38] . Crystal structures of the MSP β-chain reported by Carafoli et al. [39] show that MSP-β lacks many of the intermolecular interactions found in HGF that mediate dimerization. In HGF, the high-affinity Met-binding site is located in the α-chain with a low-affinity site in the β-chain [40] . This arrangement is reversed in MSP, with the high-affinity Ron-binding site within the β-chain and a low-affinity site in the α-chain [41] . Previous studies indicate that a monomer of MSP binds to Ron through the high-affinity site on the β-chain. This association then induces a change within the Ron extracellular domain to uncover the low-affinity α-chain-binding site. Therefore, only monomers of full length MSP are required to activate Ron and induce Ron homodimerization [38] . However, analytical ultracentrifugation and crystallographic studies reported by Chao et al. [42] showed the presence of MSP : Ron complexes with a 2 : 2 stoichiometry. These complexes were in relatively low abundance and had weaker binding affinity compared with the 1 : 1 and 1 : 2 complexes, but their presence suggests a possible role for MSP : MSP interaction within the Ron signaling complex, although the physiological relevance is currently unclear.
Although it is possible that MSP dimers could be physiologically relevant, the current evidence supports the model of a monomer of MSP activating Ron. Therefore, it is unlikely that the mechanism of inhibition shown by the hinge analogs is because of the blockade of MSP dimerization. Consequently, possible alternative mechanisms must be considered including: (i) the hinge analogs interact with Ron and prevent MSP binding. (ii) Hinge analogs bind to MSP and prevent the formation of the MSP : Ron complex by blocking binding at either the MSP α or the β sites. (iii) Hinge analogs bind to either Ron or MSP and destabilize the MSP : Ron complex or interfere with Ron homodimerization without inhibiting MSP binding to the receptor. The mechanism by which MSP hinge and Norleual inhibited MSP-dependent effects and the interaction of these compounds with MSP or Ron will be considered in future studies.
A notable property of the Met and Ron receptors is that they are capable of interacting with and activating one another [43] . Interestingly, studies have shown that Met or Ron may have a compensatory relationship. Zhao et al. [44] reported that knockdown of Ron expression in pancreatic cancer cells resulted in increased Met signaling. These studies indicate that cancer cells have dynamic interactions between growth factor systems and targeting a single system may not have the intended effect as the cells can readily compensate for the loss of the specific growth factor activity. Therefore, targeting the HGF/Met and MSP/Ron systems simultaneously with a dual inhibitor may have increased efficacy over compounds targeting a single system.
These growth factor systems make appealing targets for cancer treatment and have been the subject of investigation and development of numerous therapeutic strategies including antibodies to HGF, MSP, Met, and Ron, as well as small-molecule kinase inhibitors and HGF antagonists [45, 46] . Although there are several examples of Met/Ron dual kinase inhibitors, to the best of our knowledge, there has been no report of a small-molecule inhibitor with activity toward both HGF and MSP. These compounds represent a novel strategy to reduce the concentrations of active HGF and MSP available to pancreatic tumor cells. We would like to investigate the effect of the hinge compounds in combination with the chemotherapeutic gemcitabine as others have shown that suppressing the Met or Ron system can sensitize pancreatic cancer cells to gemcitabine-induced cell death [47, 48] . Future studies will also include testing the efficacy of MSP hinge or Norleual treatment in an in-vivo mouse model of pancreatic cancer.
Conclusion
This study shows that the hinge analogs possess dual inhibitory activity toward both the HGF/Met and MSP/ Ron systems, and suggests that a single therapeutic agent can be designed to act as a dual inhibitor of two critical growth factor system linked to aggressive behavior in various cancers including pancreatic. Given the poor prognosis of pancreatic cancer patients and the dire need for new treatments, compounds capable of inhibiting two growth factor systems involved in pancreatic cancer progression and chemotherapeutic resistance will provide a crucial addition to future therapeutic strategies. These template molecules, which have been optimized for neither biological activity nor pharmacokinetic properties, do not represent mature drug candidates, but provide a starting point for the development of high-potency dual HGF/Met : MSP/Ron system inhibitors with an optimized pharmacokinetic profile.
